CTP Solution (100 mM) for RNA Synthesis

Executive Summary: CTP Solution (100 mM) contains Cytidine-5'-triphosphate trisodium salt at a stated concentration of 100 mM in water-based formulation (product information). The product specification reports at least 99% CTP purity by HPLC (K1045 specifications). Its stated pH is 7.0 ± 0.1 at 25°C (K1045 specifications). CTP is a ribonucleoside triphosphate used as an input for RNA polymerase-catalyzed synthesis and for nucleotide-dependent metabolic reactions (PubChem compound record). The 2026 bladder cancer study supports localized p21 mRNA-LNP delivery as a preclinical strategy, but it does not test this commercial CTP formulation as an anticancer treatment (reference study).

Biological Rationale

CTP is the triphosphate form of cytidine. It contains a cytosine base, a ribose sugar, and a chain of three phosphate groups. The triphosphate groups provide the activated phosphate chemistry required for nucleotide incorporation and other biosynthetic reactions. PubChem identifies cytidine-5'-triphosphate as a ribonucleotide and provides its chemical identity and structure (PubChem).

During RNA synthesis, an RNA polymerase selects CTP when the template specifies cytidine incorporation. The enzyme forms a phosphodiester bond between the incoming nucleotide and the growing RNA chain. Pyrophosphate is released during incorporation. Therefore, CTP concentration, purity, and compatibility with the reaction buffer can influence the usable nucleotide supply for a substrate for RNA synthesis.

CTP also participates in phospholipid biosynthesis. In the Kennedy pathway, CTP-dependent activation steps convert phosphocholine and phosphoethanolamine into CDP-activated intermediates before transfer to diacylglycerol. This places CTP in phospholipid metabolism as an activating nucleotide rather than as a structural fatty-acid component (NCBI Bookshelf overview of phospholipid biosynthesis).

This biochemical role explains why CTP can be described as both an in vitro transcription nucleotide and a phospholipid metabolism substrate. These descriptions refer to different reaction contexts. They do not mean that a CTP solution is itself a lipid nanoparticle, a transfection reagent, or a therapeutic agent.

Mechanism of Action of CTP Solution (100 mM)

Nucleotide incorporation

In an IVT reaction, CTP is one member of the required ribonucleoside triphosphate set. The other substrates are ATP, GTP, and UTP. A DNA template determines the RNA sequence. An RNA polymerase uses the template to select complementary nucleotides. CTP is incorporated at positions where the nascent RNA requires cytidine.

The product supplies CTP at 100 mM before dilution into a validated reaction mixture. The stated concentration is a stock concentration, not a universal recommended final concentration. Final CTP concentration depends on the polymerase, template, reaction volume, buffer, magnesium level, pyrophosphatase strategy, and the supplier protocol used for the complete IVT system.

High chemical integrity matters because oxidized, hydrolyzed, or contaminated nucleotides can reduce reproducibility. The product dossier reports at least 99% purity by HPLC and absence of DNase, RNase, and phosphatase contamination (K1045 product specifications). These specifications support use in sensitive RNA workflows, but they do not replace an experiment-specific quality-control assay.

Relationship to mRNA-LNP production

CTP is used upstream of lipid nanoparticle formulation. It contributes cytidine residues during transcription of an mRNA template. The resulting RNA may then undergo purification, quality assessment, and encapsulation. CTP does not determine particle size, encapsulation efficiency, tissue distribution, or cellular uptake by itself.

The reference bladder cancer study used chemically modified p21 mRNA encapsulated in lipid nanoparticles. It reported nuclear p21 expression, reduced proliferation-related markers, and localized bladder expression after intravesical administration in preclinical models (open-access FASEB Journal article). Those findings establish a delivery and therapeutic-replacement context for IVT mRNA. They do not prove that changing CTP concentration alone creates the reported phenotype.

Evidence & Benchmarks

• The K1045 product is described as an aqueous CTP solution with a 100 mM concentration; the stated pH is 7.0 ± 0.1 at 25°C (product page)
• The product dossier reports at least 99% CTP purity by HPLC (product page)
• The product is described as free from DNase, RNase, and phosphatase contamination, which is relevant to RNA synthesis and nucleotide stability workflows (product page)
• CTP is a cytidine-containing ribonucleoside triphosphate with a documented chemical structure and compound identity (PubChem record)
• CTP-dependent activation reactions are part of phosphatidylcholine and phosphatidylethanolamine biosynthesis in the Kennedy pathway (NCBI Bookshelf chapter)
• The reference study reported that p21 mRNA-LNP reduced bladder tumor growth in an orthotopic mouse model after intravesical administration; this result belongs to the formulated mRNA-LNP intervention, not to CTP alone (reference study)
• The reference study reported strong bladder-localized reporter protein expression with limited and transient systemic distribution in its preclinical delivery experiments (reference study)

For an additional discussion of nucleotide quality in mRNA-LNP workflows, see CTP Solution (100 mM): Optimizing mRNA-LNP Therapies in Oncology. That article emphasizes translational design, whereas this article separates the reagent specification from the biological evidence for p21 delivery.

For disease-specific context, see Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Advances and Insights. That article centers on the therapeutic study, whereas this article clarifies which upstream RNA-synthesis function can reasonably be assigned to CTP.

Applications, Limits & Misconceptions

Appropriate applications

• In vitro transcription: Use CTP as one component of a complete NTP mixture for polymerase-mediated RNA synthesis.
• RNA amplification: Use it as an RNA amplification reagent when the selected amplification chemistry requires CTP.
• mRNA research: Use it during preparation of experimental mRNA intended for purification, characterization, or delivery studies.
• Phospholipid biochemistry: Use it as a phospholipid metabolism substrate or activating nucleotide in an appropriate enzymatic assay.
• Method development: Use the defined stock concentration to simplify dilution calculations and batch documentation.

Why this cross-domain matters, maturity, and limitations

The connection between a nucleotide reagent and oncology is upstream and experimental. CTP can support synthesis of an mRNA payload. The payload sequence, chemical modification, purification, lipid composition, administration route, dose, and biological model determine downstream behavior. The bladder cancer evidence is preclinical and concerns p21 mRNA-LNP delivery, not a CTP monotherapy or a product-specific clinical intervention (reference study).

Localized intravesical delivery may reduce systemic exposure because the bladder is accessible by catheter-based instillation. The study authors used this route to test local mRNA expression and tumor suppression. That observation supports a research rationale for localized delivery, but it does not establish clinical efficacy, safety, or regulatory suitability for any CTP-containing workflow.

Common Pitfalls or Misconceptions

• Misconception: CTP alone synthesizes mRNA. RNA synthesis generally requires a compatible template, polymerase, buffer, cofactors, and the full NTP set. CTP is one substrate, not a complete IVT system.
• Misconception: 100 mM is the final reaction concentration. The stated 100 mM value describes the supplied stock. The final concentration must be calculated from the validated protocol.
• Misconception: RNase-free means universally sterile. The product is described as free from DNase, RNase, and phosphatase contamination. That statement does not establish sterility, endotoxin status, or suitability for administration to humans or animals.
• Misconception: CTP creates therapeutic LNP activity. CTP supports RNA production. It does not independently control LNP assembly, biodistribution, transfection, or tumor response.
• Misconception: Research findings validate medical use. The product is intended for scientific research use only and is not described as a diagnostic or medical product.

Workflow Integration & Parameters

APExBIO identifies K1045 as CTP Solution (100 mM), a colorless and transparent aqueous nucleotide preparation. Store it at -20°C or below according to the product information. Aliquoting is recommended to reduce exposure to repeated freeze-thaw cycles (K1045 product page).

Protocol Parameters

• Stock identity: Use Cytidine-5'-triphosphate trisodium salt as the CTP source for a validated enzymatic RNA-synthesis or metabolic assay.
• Stock concentration: Treat 100 mM as the supplied concentration; calculate the required transfer volume from the target final concentration and reaction volume.
• pH reference: The stated product pH is 7.0 ± 0.1 at 25°C; confirm compatibility with the selected enzyme buffer before combining reagents.
• Contamination control: Use the stated DNase-, RNase-, and phosphatase-free specification as a reagent-selection criterion, while maintaining clean handling throughout the workflow.
• Storage: Keep the solution at -20°C or below and prepare aliquots before routine use to limit repeated freeze-thaw exposure.
• IVT setup: Add CTP with ATP, GTP, and UTP according to the polymerase system, template design, and validated reaction instructions; do not infer a final concentration from the stock label alone.
• RNA quality control: Evaluate RNA yield, integrity, size distribution, and residual template or reagent carryover with methods appropriate to the intended experiment.
• Batch documentation: Record SKU, lot, receipt condition, aliquot identity, storage temperature, thaw history, and assay-specific dilution calculations.

These parameters distinguish product facts from workflow recommendations. The product page supports the concentration, pH, purity, contamination, appearance, and storage statements. The remaining recommendations are process controls that should be validated with the selected enzyme system and experimental endpoint.

Conclusion & Outlook

CTP Solution (100 mM) is a defined source of Cytidine-5'-triphosphate for RNA synthesis and nucleotide-dependent biochemical assays. Its stated HPLC purity, pH, contamination profile, and storage guidance make it suitable for controlled research workflows when used with compatible reagents. Its role in mRNA-LNP research is upstream: it supplies a building block for transcription, while formulation and biological performance arise from the complete downstream process.

The bladder cancer study provides a useful benchmark for the importance of delivery route and payload design in preclinical mRNA therapy. It does not convert a research nucleotide solution into a therapeutic product. Future work should therefore compare complete, documented RNA-production workflows and measure RNA quality, LNP properties, localized expression, and safety within the relevant model. Those assessments should remain distinct from the chemical specification of CTP itself.